Thrombocytopenia affects 20-30% of infants admitted to the neonatal intensive care unit. In 25% of affected neonates (25,000-30,000 per year in the US), the thrombocytopenia is severe, and 9% of them experience clinically significant bleeding (usually intracranial). Up to 10% of severely thrombocytopenic neonates have low platelet counts lasting >30 days, prompting multiple platelet transfusions, with all their associated risks. The causes underlying the predisposition of neonates to develop thrombocytopenia are not understood, but are clearly related to the unique biological characteristics of fetal/neonatal megakaryocytes (MKs). However, there is a fundamental gap in understanding the mechanisms underlying the differences between neonatal and adult MKs, and lack of such knowledge has impaired our ability to treat neonatal thrombocytopenia and other disorders that selectively affect fetal/neonatal MK progenitors. Over the last period of support, we discovered that fetal megakaryopoiesis is characterized by a unique uncoupling of proliferation, polyploidization, and cytoplasmic maturation, and that cell-intrinsic and micro-environmental factors contribute to this pattern. Specifically, our data suggest that a pathway involving the miRNA let-7b mediates their high proliferative rate. Furthermore, we found that neonatal MK progenitors respond differently to thrombopoietin (Tpo) compared to adults and exhibit differences in Tpo receptor expression and signaling pathways. This finding is of high clinical significance, given the recent FDA approval of 2 Tpo mimetics (Romiplostim and Eltrombopag) for the treatment of thrombocytopenic adults. While some thrombocytopenic neonates are appealing candidates for treatment with these mimetics, our data suggest that simply extrapolating observations from adults to neonates would represent a serious pitfall. The objectives of the current proposal are two-fold: 1) to advance our understanding of the mechanisms underlying the unique features of fetal/neonatal megakaryopoiesis;and 2) to characterize the responses of neonatal MK progenitors to these novel Tpo agonists, with the long term goal of improving the treatment of thrombocytopenic neonates. To achieve our objectives, we designed the following Specific Aims: 1) To dissect the contributions of cell intrinsic and microenvironmental factors (Tpo and others) on the phenotype of fetal/neonatal megakaryopoiesis;2) To characterize the effects of romiplostim and eltrombopag on fetal, neonatal, and adult human megakaryocytopoiesis;and 3) To establish the platelet production rate at baseline and in response to romiplostim in newborn mice with thrombocytopenia.
These aims will be accomplished through a blend of in vitro studies on primary human MKs and in vivo studies using knockout mice and murine models of thrombocytopenia. We expect our findings to have a substantial impact on both our fundamental understanding of fetal MK biology and on the clinical management of thrombocytopenic neonates.

Public Health Relevance

Low platelet counts are common among sick newborn infants, particularly those born very prematurely, and are usually treated with platelet transfusions in an effort to decrease the incidence or severity of bleeding. Two factors that stimulate platelet production were recently approved by the FDA for the treatment of adults with low platelet counts, but studies from our laboratory suggest that the process of platelet production and the response to these factors are very different in neonates compared to adults. The studies in this proposal are of high clinical relevance, as they will determine whether and how these new medications work in neonates, with the ultimate goal of reducing the number of platelet transfusions they receive and improving outcomes.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL069990-10
Application #
8688302
Study Section
Hemostasis and Thrombosis Study Section (HT)
Program Officer
Mondoro, Traci
Project Start
2002-04-01
Project End
2016-06-30
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
10
Fiscal Year
2014
Total Cost
$293,359
Indirect Cost
$102,293
Name
Children's Hospital Boston
Department
Type
DUNS #
076593722
City
Boston
State
MA
Country
United States
Zip Code
02115
Liu, Zhi-Jian; Hoffmeister, Karin M; Hu, Zhongbo et al. (2014) Expansion of the neonatal platelet mass is achieved via an extension of platelet lifespan. Blood 123:3381-9
Ferrer-Marin, F; Gutti, R; Liu, Z-J et al. (2014) MiR-9 contributes to the developmental differences in CXCR-4 expression in human megakaryocytes. J Thromb Haemost 12:282-285
Ferrer-Marin, F; Gutti, R; Liu, Z-J et al. (2014) MiR-9 contributes to the developmental differences in CXCR-4 expression in human megakaryocytes. J Thromb Haemost 12:282-5
Liu, Zhi-Jian; Sola-Visner, Martha (2011) Neonatal and adult megakaryopoiesis. Curr Opin Hematol 18:330-7
Ferrer-Marin, F; Chavda, C; Lampa, M et al. (2011) Effects of in vitro adult platelet transfusions on neonatal hemostasis. J Thromb Haemost 9:1020-8
Liu, Zhi-Jian; Italiano Jr, Joseph; Ferrer-Marin, Francisca et al. (2011) Developmental differences in megakaryocytopoiesis are associated with up-regulated TPO signaling through mTOR and elevated GATA-1 levels in neonatal megakaryocytes. Blood 117:4106-17
Hu, Zhongbo; Slayton, William B; Rimsza, Lisa M et al. (2010) Differences between newborn and adult mice in their response to immune thrombocytopenia. Neonatology 98:100-8
Ferrer-Marin, Francisca; Liu, Zhi-Jian; Gutti, Ravi et al. (2010) Neonatal thrombocytopenia and megakaryocytopoiesis. Semin Hematol 47:281-8
Sola-Visner, Martha; Sallmon, Hannes; Brown, Rachel (2009) New insights into the mechanisms of nonimmune thrombocytopenia in neonates. Semin Perinatol 33:43-51
Josephson, Cassandra D; Su, Leon L; Christensen, Robert D et al. (2009) Platelet transfusion practices among neonatologists in the United States and Canada: results of a survey. Pediatrics 123:278-85

Showing the most recent 10 out of 24 publications